Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally

Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.

RedBloodCellsOnWhite_1200x675
First Filing For Novel Anemia Therapy Vadadustat • Source: Shutterstock

Mitsubishi Tanabe Pharma Corp. (MTP) has made the first approval filing globally, in Japan, for vadadustat (MT-6548), its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) licensed from US venture Akebia Therapeutics Inc.

The pioneering regulatory submission, if approved, is expected to lead to the first launch of the molecule worldwide. It also...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia